Walter Flamenbaum
Director/Board Member at Hudson Hall
Profile
Walter Flamenbaum is the founder of Heart Metabolics Ltd.
He currently holds director positions at Hudson Opera House, Hudson Hall, and Stuart Therapeutics LLC.
Previously, he held CEO positions at Plumtree Group Ltd.
and director positions at Oscient Pharmaceuticals Corp., Washington & Jefferson College, and OSE Immunotherapeutics SA. He also served as a professor at Tufts University, The Mount Sinai Hospital, and Icahn School of Medicine at Mount Sinai.
Additionally, he was a partner-emeritus at Paul Capital Partners LP and Paul Capital Advisors LLC, and a managing partner at The Channel Group.
He holds a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Washington & Jefferson College.
Walter Flamenbaum active positions
Companies | Position | Start |
---|---|---|
Hudson Hall | Director/Board Member | - |
Hudson Opera House | Director/Board Member | - |
Stuart Therapeutics LLC
Stuart Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then. | Director/Board Member | 31/12/2018 |
Former positions of Walter Flamenbaum
Companies | Position | End |
---|---|---|
MINK THERAPEUTICS, INC. | Director/Board Member | 30/12/2021 |
OSE IMMUNOTHERAPEUTICS | Director/Board Member | 25/03/2020 |
Paul Capital Partners LP
Paul Capital Partners LP Investment ManagersFinance Founded in 1991 by Philip Paul, Paul Capital Partners LP is a private equity firm located in San Francisco with additional offices in New York City, Hong Kong, London, Paris and São Paulo. | Corporate Officer/Principal | 31/10/2019 |
Washington & Jefferson College | Director/Board Member | 31/12/2017 |
Paul Capital Advisors LLC
Paul Capital Advisors LLC Financial ConglomeratesFinance Part of Paul Capital Partners LP, Paul Capital Advisors LLC provides investment services. The private company is based in San Francisco, CA. | Corporate Officer/Principal | 31/12/2015 |
Training of Walter Flamenbaum
The Trustees of Columbia University in The City of New York | Doctorate Degree |
Washington & Jefferson College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
OSE IMMUNOTHERAPEUTICS | Health Technology |
MINK THERAPEUTICS, INC. | Health Technology |
Private companies | 19 |
---|---|
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
Paul Capital Advisors LLC
Paul Capital Advisors LLC Financial ConglomeratesFinance Part of Paul Capital Partners LP, Paul Capital Advisors LLC provides investment services. The private company is based in San Francisco, CA. | Finance |
Paul Capital Partners LP
Paul Capital Partners LP Investment ManagersFinance Founded in 1991 by Philip Paul, Paul Capital Partners LP is a private equity firm located in San Francisco with additional offices in New York City, Hong Kong, London, Paris and São Paulo. | Finance |
The Mount Sinai Hospital
The Mount Sinai Hospital Hospital/Nursing ManagementHealth Services The Mount Sinai Hospital provides medical and healthcare services. The company was founded in 1952 and is headquartered in New York, NY. | Health Services |
The Channel Group
The Channel Group Investment ManagersFinance The Channel Group is a venture management and corporate advisory business headquartered in Harrison, New York. | Finance |
Walter Reed Army Medical Center | |
Walter Reed Army Institute of Research | |
Uman Pharma, Inc.
Uman Pharma, Inc. Pharmaceuticals: GenericHealth Technology Uman Pharma, Inc. develops, manufactures, and markets generic injectable pharmaceutical products. The company was founded in December 20, 2007 and is headquartered in Montreal, Canada. | Health Technology |
Orphan Synergy Europe-Pharma SA
Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France. | Health Technology |
Plumtree Group Ltd.
Plumtree Group Ltd. Packaged SoftwareTechnology Services Part of HgCapital LLP, Plumtree Group Ltd. is a British company that develops and distributes electronic document management software. The private company is based in Keyworth, UK. Plumtree Group was acquired by Ideagen Ltd., part of HgCapital LLP from July 07, 2022 on December 17, 2012 for $4.03 million. | Technology Services |
Heart Metabolics Ltd.
Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Health Technology |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Griffintown Capital Partners LLC | |
OSE Pharmaceuticals | |
Hudson Opera House | |
Hudson Hall | |
Norphan Pharmaceuticals, Inc. | |
Allergan Research Corp. | |
Stuart Therapeutics LLC
Stuart Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then. | Commercial Services |
- Stock Market
- Insiders
- Walter Flamenbaum